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FEW observations have so far been made on the events occurring in solid
tumours, especially large ones, when they undergo regression under the action of
anti-tumour agents. This communication reports a detailed study of two treated
tumours, the mouse plasma cell tumour Adj-pc-5 which regresses regularly even
when extremely large and necrotic, and the Walker carcinosarcoma 256 which
does not respond well when large to treatment with the same chemotherapeutic
agent, N,N-di-2-chloroethylaniline (" aniline mustard ", CB1074).
It is well established that transplanted tumours regress less readily with
anti-tumour agents when treatment is delayed until the tumours are large
(Larionov, 1959; Martin et al., 1962). Hirschberg (1963) in a comprehensive
review lists 479 tumour systems which respond to one or more drugs when treated
on or near the day of transplantation, but there are few reports of complete
regression of tumours treated when they are old: Connors and Roe (1964)
reported that 560% of 7-day old Walker tumours regressed with melphalan:
Sugiura and Stock (1955) reported that over 80% of 6 tumours (Flexner-Jobling,
Jensen sarcoma, carcinoma 1025, Ridgeway osteogenic sarcoma, Gardner lympho-
sarcoma and sarcoma R39) regressed with various phosphoramides when treated
7 days after transplantation. Seven-day old Ehrlich and Krebs 2 carcinomas and
sarcoma 180 regressed with various drugs in 100% of cases when in the ascitic
form, but not when in the solid form (Sugiura and Creech, 1956). Actinomycin D
caused regression of a solid lymphoma and the Krebs 2 carcinoma when they were
as large as 12 and 10 mm. across respectively (Di Paolo, 1960). The YPC-1
plasma cell tumour regressed with cyclophosphamide when as old as 16 days
(Yancey, 1964). The recent demonstration of Whisson and Connors (1965a, b)
that the mouse plasma cell tumour Adj-pc-5 would regress with a single treatment
dose of " aniline mustard " even when the tumours were up to 21 days old, 5 cm.
across and 8 g. in weight, provided an unusual opportunity to investigate what
occurred in large tumours during regression.
In particular, it was sought to answer the following questions:
1. How soon after treatment begins do the tumour cells die?
2. In what region ofthe tumour, large and partly ischaemic, are the cells killed?
3. What happens to living cells (Goldacre and Sylven, 1962) in the ischaemic
region?R. J. GOLDACRE AND M. E. WHISSON
4. What proportion of the cells are killed, and how many remain alive after
the chemotherapeutic agent has been destroyed or excreted?
5. What part do immune responses play in disposing of any tumour cells left
alive after the chemotherapeutic agent has disappeared?
To help the interpretation, a study was also made of the large established rat
Walker tumour which is more resistant to aniline mustard when large (e.g. 7 days)
but more sensitive when small (e.g. 1 day). The resistance develops markedly
with increasing size, and the tumour therefore forms a useful contrast with the
Adj-pc-5 tumour in which resistance increases much less with increase in size.
An attempt was made to determine what feature conferred the resistance.
MATERIALS AND METHODS
The Adj-pc-5 mouse plasma cell tumour originally induced with Freund's
adjuvant and heat-killed staphylococci by Potter and Robertson (1960) and kindly
supplied by Dr. Potter, was implanted by trochar and cannula into BALB/c
8-week-old mice. The Walker carcinosarcoma 256 was similarly transplanted into
the Chester Beatty strain of Wistar rats, 6 weeks old. The anti-tumour agent
N,N-di-2-chloroethylaniline (" aniline mustard ") synthesized by Mr. J. L. Everett
by the method of Robinson and Watt (1934) was dissolved in arachis oil and
injected intraperitoneally. For both mice and rats doses of 60 mg./kg. were used.
The vitality of the tumours was studied in two ways, both by the dye exclusion
test on tumour cell suspensions, and by transplantation. The dye exclusion test
usinglissamine green (Goldacre and Sylven, 1959; Holmberg, 1961) and improved
as follows, was used. A small piece oftumour was placed in a drop of physiological
saline on a slide, and teased with needles until the cells were dispersed. On the
end of the slide was placed a drop of 20% lissamine greenV (Gurr) and around the
drop were placed four small dabs of vaseline from a syringe. With the corner of a
coverslip a drop of dye solution, estimated roughly to be about one-tenth the
volume of the tumour cell suspension, was placed alongside the latter and then
stirred in. A coverslip was then placed over the mixture and pressed with needles
so as to flatten the vaseline dabs, until with the microscope it could be seen that
the coverslip was resting lightly on the tops of the tumour cells, which when alive
appeared as white spheres on a green background. One judged whether the cells
were a lighter or darker green than the background and thus the test is more
decisive than the usual test with eosin or trypan blue, where presence or absence
of staining of the cell is sometimes difficult to determine. This refinement is
possible because of the high depth of colour oflissamine green in a layer equal to
the thickness of a cell, the low toxicity of the dye enabling a high concentration to
be used, and the low affinity of the dye for the protein in the medium.
Lissamine green was also used for quite a different purpose, to mark out the
ischaemic zones (Goldacre and Sylven, 1959 and 1962). An intravenous injection
of 2% dye solution into the tail vein of tumour-bearing mice (0.5 ml.) and rats
(5 ml.) was given about 5 minutes before the animals were killed in ether. The
animals were then dissected and the tumours examined by bisecting in an equa-
torial plane. The ischaemic regions, usually centrally placed but sometimes
approaching the tumour surface, were uncoloured by the dye, whereas the well-
vascularized peripheral regions were coloured a deep green, owing to the rapid
penetration of the dye into the intercellular spaces of the tumour. The tumour
802EXPERIMENTAL TUMOUR REGRESSION WITH NITROGEN MUSTARD 803
oedema fluid was also strongly coloured in the plasma cell tumour (but not in the
Walker tumour, whose fluid was mainly in the necrotic zone) and was carefully
soaked up in gauze during the dissection to prevent its running on to the cut
surface of the tumour. lf necessary, after wiping, a second cut was made parallel
to the first with a clean knife.
To determine the number of living cells in the tumour, small pieces of tumour
about 1 mm.3 were cut with a pointed scalpel from various representative tumour
regions both ischaemic and non-ischaemic, and dispersed in saline on slides by
teasing with 2 needles for the vitality test. (As a point ofinterest, it was found by
the dye exclusion test that tumour cells were killed instantly when their suspension
was diluted 10 times with distilled water, and that a scalpel blade contaminated
with living tumour cells could be sterilized from them by dipping it into distilled
water for a few seconds. The blades used during the dissection were routinely
dipped in distilled water and wiped on filter paper before dissecting a new part of
the tumour. The results were frequently checked with new blades.) The
proportion of living cells in about 12 representative fields in each sample was
counted, and from the dimensions of the tumour and of its ischaemic regions a
rough estimate was made of the number of living cells in the tumour.
Treatment ofmouse tumours was begun on the 19th day after transplantation.
when the tumours were an average of 26 mm. long and 5 g. in weight, with
considerable necrosis. The rat Walker tumour was treated on the 7th day after
transplantation at which time necrosis was found to be considerable and to
advance rapidly (Goldacre and Stojanovi6, unpublished). After treatment had
begun, three tumours of each type were investigated at daily intervals until the
5th day, and thereafter at longer intervals.
RESULTS AND DISCUSSION
A. Mouse plasnma cell tumour
1. The time of onset of necrosis was somewhat variable. Most tumours had
necroses by the 13th day, and all after the 18th day (Table I).
TABLE I. Time of Onset of Necrosis in Mouse Plasma Cell Tumour
Age of tumour, days . 10 . 11 . 12 13 . 14 . 15 16 17 1S 19 20 21
No. oftumours with necrosis . 0 1*. 0 5t. 4 2 2 . 1 3 16 9
No.oftumourswithoutnecrosis. 2 2 3 0 2 0 0 3 0 0 0 0
* Necrosis is very small (< 1 mm3) t 3 necroses very small.
2. Few living cells were found in the ischaemic zone, and in 44 out of 62, or
70%0 ofthe tumours, none was found at all. Ofthe few ischaemic zones which did
have living tumour cells, most had less than 3%0. This contrasts with the high
figures for the Walker tumour (see below).
3. The effect of treatment with the anti-tumour agent was as follows:
Day 0. The peripheral vascularized* or non-ischaemic (N.I.) zone of the
tumour had an average of 90°/ living cells in it, contrasting with 0.00%0 in the
ischaemic zone ofmost ofthe tumours. This vascularized N.I. zone in places was
often over 8 mm. thick.
* Used in this paper in the sense ofcontaining patent vessels. The term
"non-ischaemic " (N.I.)
is more accuirate but more cumbersome.0. J. GOLDACRE AND M. E. WHISSON
Days 1 and 2.-The proportion ofliving cells in the N.I. zone dropped to 5000.
Day 3.-The proportion of living cells in the N.I. zone was now only 0-0300.
The blood supply, however, remained intact, as shown by the green colour of the
N.J. zone after intravenous dye injection (Fig. 1) and so was available to remove
the dead cells later. The dead cells remained in situ, some as swollen " ghosts
about three times the previous diameter.
Day 4.-Between day 3 and day 4 the tumour shrank dramatically to approxi-
mately the size of the original ischaemic zone (about 4-1 of original volume)
(Fig. 1). The tumour cells burst and formed a milky suspension of cytoplasmic
particles, which flowed away and caused the shrinkage. On day 4 the N.I. zone
was very thin, tough and difficult to disperse in saline with needles. This con-
trasted with its jelly-like consistency before treatment. The N.I. zone consisted
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FIG. 1. Diagram showing changes in dimensions of ischaemic (white) and non-ischaemic
(stippled-but green in the lissamine green test for tumour blood supply) zones of the plasma
cell tumour at vaiious times after mustard treatment.
inainly oftough, dense fibres; the sparse fibres in the untreated tumour were now
drawn together by the shrinkage. Very few living cells could now be found in this
zone, but their percentage was 370 owing to the bursting and removal of most of
the dead cells. The total living cells in the tumour had now dropped from 109
to i05 (Fig. 2).
Day 5.-Further reduction ofliving tumour cells to approximately 6000. The
N.I. zone consisted now almost entirely of compact (dead) fibres entangling very
few tumour cells, and numerous small (8 It) round cells, with large nuclei and scant
cytoplasm and staining as lymphocytes, which were absent before. The tumour
now continued to shrink at a much slower rate.
Day 17.-Ischaemic zone now shrunken to 300 of original volume. Only
about 400 living cells left per tumour.
Day 60. No tumour found on dissection.
4. A rough estimate ofthe total number ofliving tumour cells in the tumour at
various times is given in Fig. 2.
804EXPERIMENTAL TUMOUR REGRESSION WITH NITROGEN MUSTARD 805
5. Tumours grew (4 takes out of 4 implants) when implanted into mice which
had 2 days before been given an otherwise therapeutic dose of the mustard.
This showed that the mustard had in 2 days become ineffective, and was unavail-
able to deal with the living tumour cells remaining in mice on day 3 (Fig. 2).
A half-life for the drug of 3*7 hours in water containing 25% acetone at 370 C.
was reported by W. Davis (private communication).
6. Though most cells died 3 days after treatment, irreversible damage was
shown to occur much earlier. Tumour implants into normal mice were made at
various time intervals after donor mice were treated with a therapeutic dose ofthe
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Fro. 2.-Graph showing approximate number ofliving cells in plasma cell tumour
at various times after treatment.
drug. It was found that 8 out of 8 implants taken at I hour after treatment grew
in the new hosts, whereas 0 out of 8 implants taken at 3 hours grew. Since
maximum blood concentration of drug (given i.p.) occurs after some considerable
time, damage is probably more rapid after contact with drug than these figures
suggest.
7. Mice were implanted by trochar from the ischaemic zone, and 8 out of 10
implants did not take. This again shows the lack of vitality of this ischaemic
zone, and contrasts with that of the Walker tumour (see below) where takes were
70% (Goldacre and Stojanovic, unpublished).
8. Many living lymphocytes were found after the 3rd day in the peripheral
parts of the tumour from which they had previously been excluded. They
outnumbered the tumour cells by 10: 1.
9. The femoral bone marrow was blown out into a drop ofsaline on a slide on
day 3, and 95% ofthe cells found to be alive. The marrow was fluid and reduced
in volume, but later increased and became a solid plug again by day 8.R. J. GOLDACRE AND M. E. WHISSON
10. Mice whose tumours had been caused to regress by nurstard treatment
were reimplanted with the tumour by trochar and cannula (about 107 cells) and
found to be resistant. A similar result was found in a parallel study by WXhisson
and Connors (1965a).
Thus the view of Berenbaum (1964) that mustard treatment may be dis-
advantageous since it may weaken the immune defences of the host, is shown not
to apply to this system. This is also supported by results 8 and 9. The continued
death of the residual tumour cells after the mustard has disappeared may partly
depend on the immunization of the animal. The low numbers (105) of living
tumour cells remaining after 3 days would be expected to be susceptible to attack
by the size of the immune reaction, which after 23 days could reject at least 107
cells. Also, the apparent selective killing of tumour cells by the anti-mitotic
drug, even in the presence of some normal cells dividing at about the same rate,
would seem therefore to depend partly on the subsequent immune attack on the
remaining tumour cells, and the absence of an immune attack on the remaining
normal cells, which, in contrast to the tumour cells, would then be able to build
up their numbers again.
Several factors appear to contribute to the success of the mustard treatment
of this tumour:
1. The presence of only moderate ischaemic regions containing almost no
living cells, which is unusual (Goldacre and Sylven, 1962; Thomlinson, 1960).
The failure of 80% of the ischaemic zone implants to take is consistent with the
absence of living tumour cells in this zone in 70%0 of the tumours investigated
(and very low in the remaining 300), and with the cure rate of 85% of mustard-
treated mice reported by Whisson and Connors (1965a).
2. The immunization of the mouse following the death of the cells in the N.I.
zone, which allows the mouse to kill the small number of residual cells not killed
by the mustard, especially those not accessible to the drug in the ischaemic zone.
3. The sensitivity of the tumour cells to the mustard, and the insensitivity of
the bone marrow in the dose needed. The sensitivity ofthe tumour may be partly
due to a chemical transformation ofthe drug by the tumour (Whisson and Connors,
1965b, 1966; Connors and Whisson, 1966) possibly with release of the more toxic
p-hydroxy derivative in the tumour. It is pertinent to note however that even
small (10 day) Adj-pc-5 tumours are resistant to most drugs, and even to aniline
mustard they show a greater resistance than some other commonly used trans-
plantable tumours including the Walker tumour. The unique feature of the
plasma cell tumour is its failure to show any great increase in resistance with
increasing size.
B. The Walker tumour
A parallel study was made on the Walker tumour 7 days old, which at this
age is known not to respond well to the same treatment. The results are as
follows:
1. This tumour had relatively much more ischaemic zone than the plasma
cell tumour. It has previously been shown, by intravenous lissamine green
injection, that the explosive expansion of the ischaemic zone begins on the 7th
day after transplantation (Goldacre and Stojanovic unpublished) and within a
few days may occupy all but a paper-thin vascularized zone at the periphery.
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2. The proportion of living cells in the ischaemic zone was very high, the
average on treatment day being 25%.
3. The results of treatment are as follows:
During the first week the treated tumours remained the same size while the
controls grew rapidly. The proportion ofliving cells in the N.I. zone fell suddenly
from 50 0 to 1% between the 5th and 7th day after treatment began. As this
zone was then only about a millimetre thick, compared with a tumour diameter of
about 50 mm., no marked reduction occurred in the size of the tumour, which
remained for the next 6 weeks approximately equal to the size of the original
ischaemic zone of the tumour (Fig. 3). In the peripheral zone from the 7th day
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FIG. 3. Graph showing average maximum diameters of 9 WValker tumours,
at various times after drug treatment.
onwards the living cells became interspersed with and outnumbered by living
lymphocytes, ratios ofup to 4: 1 being found. A remarkable feature also was the
presence of large living granular phagocytic cells containing up to 8 tumour cells,
and also outnumbering the tumour cells up to 3: 1. That the tumour cells were
multiplying faster than they could be destroyed by the immune defences of the
body was shown by some longer-term results between 27 and 47 days after treat-
ment. Though the tumours were approximately the same size as on treatment
day, the percentage living cells in the peripheral vascular zone had in most cases
greatly increased from the value of 10% at 7 days, as in Table II.
TABLE II.-Percentage ofLiving Cells Present After Treatment
% living cells in
Number Days after ^ A
of tumours treatment N.I. zone I. zone
1 . 27 . 40, 5 0.1
1 . 40 . 0.01 0.00
4 . 43 50, 10, 80,4 30, 2, 0, 4R. J. GOLDACRE AND M. E. WHISSON
The figures for the rat examined 40 days after treatment suggest that that
animal may have ultimately been cured. Indeed, a few ofthe treated rats which
were not killed in the experiment survived over 3 months, the others dying with
massive tumours. A feature of the results with both tumours was the variable
number ofliving tumour cells, particularly intheischaemic zone, at anygiventime.
This may account for the variable response to treatment of tumours of the same
age. After 6 weeks the Walker tumour cells tended to invade the capsule and
form metastases in the liver and lungs, which were found on killing the animals for
examination.
A
VASCULAR ISCHAEMIC\X
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1 2 3 4 5 6 7 a
Days after treatment
FIG. 4.-Diagram showing semi-quantitatively the changes in the cell population of the
Walker tumour up to 7 days after treatment with the mustard.
These observations underline the importance ofthe host's defences. Although
in both the plasma cell tumour and the Walker tumour most of the accessible
tumour cells were killed within a week, the Walker tumour continued probably for
at least two reasons:
1. The replenishment ofthe peripheral parts ofthe tumour from the numerous
living tumour cells in the ischaemic zone (25% on treatment day) which were
never reached in significant concentration by the mustard. Even the turbid
fluid taken from the ischaemic zone (marked out by i.v. lissamine green injection)
of untreated Walker tumours of various ages, and in which no attempt had been
made to include solid (necrotic) tissue, was found to produce new tumours in 70%
of cases when injected (0.5 ml.) subcutaneously in rats (Goldacre and Stojanovi6,
unpublished).
2. The proportion ofliving cells remaining in the peripheral part ofthe Walker
tumour after the mustard had disappeared, though only 1 %, was still 30 times that
remaining in the plasma cell tumour, and the absolute number of cells remaining
in the larger Walker tumour was about 108 as opposed to 105 in the mouse tumour.
This larger amount seemed to saturate or more than saturate the host's defences,
and the ratio of defending cells to tumour cells in the periphery of the Walker
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tumour was observed to be considerably less than in the mouse plasma cell tumour.
This explanation is supported by the observation of Connors and Roe (1964)
that small Walker tumours regress completely with a single dose ofaniline mustard.
Assuming that the cells in small and large tumours have the same inherent
sensitivity to the drug, the larger absolute number of tumour cells left alive after
drug treatment in large tumours (in both peripheral and ischaemic zones) in
relation to the host's limited immune defences would appear to be decisive.
The significance of the ischaemic zone for tumour regression is indicated by a
number of experiments. The point at which it becomes difficult to cause regres-
sion of many tumours both by drugs and radiation seems to coincide with the
sudden appearance ofextensive ischaemia in the tumours. Roughly speaking, this
often occurs whenthe tumoursreach a size ofabout 10mm., atanage ofabout 10-15
days inthe mouse-thoughthere may be considerable variationinthetime between
various strains of mouse-and in the Walker tumour used, usually at 7 days.
Thus, in a series of tumours of increasing age, Larionov (1959) found that
Dopan suddenly became ineffective when the tumour exceeded an age of 13 days.
Connors and Roe (1964) found that the percentage of complete regressions of the
Walker tumour treated with melphalan on days 1, 3, 5, and 7 were 100, 100, 81 and
53, respectively. Ischaemia became extensive on day 7 in this tumour (Goldacre
and Stojanovic, unpublished). Martin and Fugmann (1960) found that animals
bearing 7 to 20 day old tumours of various types had a negligible cure-rate by
chemotherapy or surgery alone; but when the tumours were surgically reduced in
size to 3-6 mg., and all the necrosis removed, subsequent chemotherapy gave
high rates of cure.
A similar indication is given by quite a different kind of experiment with
radiation supplemented by hyperbaric oxygen. Anoxic tumour cells are radiation-
resistant (Scott, 1957) but even hyperbaric oxygen would not penetrate far into
the ischaemic zone. Suit, Schlachter and Andrews (1960) reported that animals
with tumours 7-10 mm. across responded better to X-rays in 4 atmospheres
pressure of oxygen than those in air, whereas the extra oxygen in the blood gave
no better response with tumours 10-15 mm. across.
There seems to be a widespread impression that necrotic or ischaemic regions
of tumours are wholly dead. That this is not so was concluded by Thomlinson
(1960) from a study of the response of small and large tumours to X-rays in
animals breathing oxygen at high pressure, where the extra oxygen again only
increased the anti-tumour effect of the X-rays in small tumours; and also by
Goldacre and Sylven (1959 and 1962) who transplanted ischaemic tumour tissue,
marked out by a previous intravenous injection oflissamine green into the tumour-
bearing animal, and obtained a high proportion of takes. Algire and Chalkley
(1945) ligated the vessels of the mouse mammary carcinoma and found that the
tumours became completely necrotic, but that a few days later new blood vessels
were formed on the edge ofthe tumour and growth was resumed. This is perhaps
not surprising since the ischaemic tumour is somewhat in the same position as an
ordinary tumour transplant, which also at first has no blood supply. Using the
Walker tumour, Bernard et al. (1955) obtained similar results. In addition, the
rats then rejected further ordinary implants, but could not prevent the regrowth
of the original much larger ischaemic tumour. Evidentlv the number of living
cells in the ischaemic tumour in relation to the strength of the host's immune
response is critical in determining whether the tumour will resume growth, and ourR. J. GOLDACRE AND M. E. WHISSON
present experimental results can be partly interpreted in this light. In this
connection the report of Galton (1961) is of interest, that regional perfusion with
very high concentrations of cytotoxic drugs, sufficient to damage even nerve and
muscle, did not prevent recurrence in some human tumours, owing, presumably,
to living cells in the ischaemic zone inaccessible to the drugs, and the weak
immunological response.
Owing to variation in the sensitivity of individual tumour cells to drugs at the
time of treatment, and to the inaccessibility of some of them to the drug, it is
difficult to kill all the tumour cells with any feasible dose ofdrug. The destruction
of the cells remaining after the drug has disappeared must depend on the immune
defences of the host. The significance of the latter in chemotherapy has been
investigated by Martin andhis colleagues (Martin and Fugmann, 1960; Martin,
1961; Martin, Fugmann and Hayworth, 1962; Martin et al., 1964). Cure rates
in animals bearing various tumours were greatly reduced when the host's defences
were nullified by cortisone, whether treatment was by anti-tumour drugs or by
drugs plus surgery. Conversely, when the defences were stimulated by the use of
Zymosan (a yeast cell-wall polysaccharide), the cure rate was increased consider-
ably above that produced by drugs plus surgery. Martin et al. (1964) state:
"The resultant data show that a cure can never, or only rarely, be effected on
large, well-established transplanted tumours by chemotherapy alone, immuno-
therapy (Zymosan) alone, or surgery alone ".
We found that most tumour cells died from the drug between the third and
fourth day with the plasma cell tumour, and between the fifth and seventh day
with the Walker tumour. However, there is evidence that irreversible damage
to the cells may occur much earlier than this without killing them at the time
(compare plasma cell tumour results 3, 4 and 6 above). In a cytological study of
the Walker tumour, treated with HN2 at age 4-10 days, Koller (1948) found that
8 hours after treatment some tumour cells had dumb-bell shaped nuclei due to the
failure ofnuclei to separate attelophase owing to chromosome stickiness. Between
24 and 48 hours, there were fragmented chromosomes, and cell proliferation
stopped completely for 3-7 days, and then began again. The loss of chromosome
segments was associated with the death of the cell, and with arrest of tumour
growth. With the ascites form of the Walker tumour treated with phenylalailine
mustard, Koller and Veronesi (1956) found that the number of injured cells was
greatest at 72 hours after treatment, the cells showing ' anaphase pyknosis".
After 72 hours, there was a great increase in the number of histiocytes or stroma
cells in the tumour.
Information such as that reported above on- the time of death of the cells aind
the proportion remaining unkilled could be used to work out efficient drug schedules
with repeated doses. One wishes to give as little drug as possible. It would seem,
therefore, unnecessary to give a second dose before the cells damaged by the first
dose have died (i.e. at 4 and 7 days in the tumours investigated); to the extent
that the cells escaping death did so because they were at an insensitive phase of
the cell cycle at the time of treatment, it would be desirable to wait as long as
possible before the second dose (provided no great multiplication occurred) so as
to allow the phases to become as randomly distributed as possible in order to kill
with the second dose the same proportion as before. For rexample, if one knew
that after 7 days all but 1% of the accessible cells were dead, it might be expected
that a second dose given then would kill all but 0.010% and so on. Of course, this
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does not deal with the separate problem of the inaccessible cells in the ischaemic
zone. These might be slowly destroyed by preventing increase in the cells there
through inhibiting, by drug, further expansion of the tumour, and by preventing
the repopulation ofthis zone by migration inwards ofthe peripheral living tumour
cells (as the lymphocytes, etc., did) by destroying those outside the ischaemic
zone; it might be expected that their demise in time in an unfavourable anoxic
medium, and their destruction by the persisting immune defence as they slowly
migrate out, might reduce their total number to below that which can be dealt
with by the immune defence alone. Information on the time ofsurvival ofliving
tumour cells in the ischaemic zone would be of interest.
Some further work needs to be done to assess more completely the relative
contributions to tumour regression of (a) living cells in the inaccessible ischaemic
zone and (b) the number of tumour cells left alive after the drug treatment, in
relation to the existing capacity of the induced immune response. This could be
done when a tumour becomes available having cells ofsensitivity equal to that of
the Adj-pc-5 tumour, but a much higher proportion ofliving cells in the ischaemic
zone when the tumour is large. Some preliminary work on other tumours of the
Adj-pc-5 series suggests that such a tumour might occur in this group.
It would also be interesting to know whether or not living tumour cells occur
in the ischaemic zone of the Burkitt African lymphoma, a human tumour which
often regresses completely with chemotherapy even when large (Burkitt, Hutt and
Wright, 1965).
SUMMARY
1. The lissamine green dye exclusion test for cell death, combined with re-
transplantation of tumour fragments, has been used to study the changes occur-
ring in the vascular and ischaemic zones oftwo transplantable tumours undergoing
regression after treatment at an advanced stage with N,N-di-2-chloroethyl aniline
(aniline mustard).
2. One of the tumours, the Adj-pc-5 mouse plasma cell tumour, readily
undergoes permanent regression after treatment when large (up to one third ofthe
body weight), whilst the other, the Walker tumour ofrats, almost never regresses
completely unless treatment is given shortly after transplantation.
3. In the vascular zone ofthe plasma cell tumour, lethal injury, as detected by
the failure oftransplanted fragments to grow, was demonstrable within 3 hours of
injection of the drug. Cell death, as detected by dye uptake, increased rapidly
between the second and third days, leaving only 003% of dye-excluding cells.
Cell lysis, accompanied by rapid shrinkage of the vascular zone, occurred on the
fourth post-treatment day. Removal ofthe ischaemic region ofthe tumour, now
firmly encapsulated in the fibres derived from the lysed vascular zone and invaded
by lymphocytes and phagocytic cells, occurred much more slowly.
4. In the vascular zone of the Walker tumour death of cells, as measured by
dye uptake, occurred later, becoming obvious on the fifth day after treatment.
After seven days there were still many cells (one per cent) alive in this zone.
Although a decrease in the number ofliving cells was also seen to occur eventually
in the ischaemic zone, many living cells were still found there 43 days after
treatment with the drug.
5. Factors involved in the curability ofone tumour and the incurability ofthe
other are discussed and may be summarized as follows:812 R. J. GOLDACRE AND M. E. WHISSON
(a) Whereas about 250 ofthe cells in the inaccessible ischaemic zone ofthe Walker
tumour were alive, no live cells could be found in this zone in most of the
plasma cell tumours.
(b) The total number ofviable cells remaining within a few days ofdrug treatment
was only 105 in the plasma cell tumour compared with a residuum of 108 in the
Walker tumour.
(c) Chemotherapy did not prevent the development ofimmunity and the immuno-
logical resistance of the mice to the plasma cell tumour measured after total
regression had occurred, was sufficient to reject 107 cells. Further work is
required to elucidate the relative contribution ofthese factors.
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